Forbion related stories
All articles and analysis
AM-Pharma racks up $176mAM-Pharma B.V., a Dutch developer of treatment for acute kidney injury, has raised additional funding of $52 million, increasing its recent total tally to $176 million.
- Roche completes Promedior acquisition
Roche has closed its previously announced acquisition of Lexington, Massachusetts-based Promedior, a biotech company.
Azafaros procures about $28 mn Series AAzafaros, a Dutch provider of treatments for rare metabolic disorders, has raised about $28 million in Series A financing.
Roche to buy VC-backed biotech firm PromediorRoche has agreed to acquire Lexington, Massachusetts-based Promedior, a biotech company. According to terms of the agreement, Roche will make an upfront cash payment of $390 million. Promedior's backers include Morgenthaler Ventures, HealthCare Ventures, Forbion, Easton Capital, Fibrotec Ventures and Polaris Partners.
- Achilles Therapeutics lands Series B funding
UK-based Achilles Therapeutics, a biopharmaceutical company, has secured 100 million pounds in Series B funding. RA Capital Management led the round. Goodwin's London life sciences practice advised Achilles on the fundraising.
Venture-backed Milestone prices Nasdaq IPO to raise $111 mlnMontréal-based cardiovascular drug maker Milestone Pharmaceuticals Inc has priced its Nasdaq Stock Market initial public offering of 5.5 million common shares at US$15 per unit. The company expects to see proceeds of about $111 million (US$82.5 million). Founded in 2005, Milestone is the developer of etripamil, a nasal spray formulation of calcium channel blockers used to terminate episodes of transient cardiovascular conditions. Milestone raised roughly $220 million in financing. This includes $105 million raised last year /canada/2018/10/milestone-pharmaceuticals-secures-80-mln-in-rtw-led-round/ led by RTW Investments and joined by BDC Capital, Domain Associates, Fonds de solidarité FTQ, Forbion, GO Capital, Novo Holdings, Pappas Capital, Tavistock Group, Tekla Capital Management and Venrock.
Venture-backed Milestone seeks up to $115 mln in Nasdaq IPOMontréal-based cardiovascular drug maker Milestone Pharmaceuticals has filed a preliminary prospectus with the U.S. Securities Exchange Commission for an initial public offering. The company is seeking up to $115 million (US$86 million) from an offering of common shares on the Nasdaq Global Market, the filing said. It intends to list under the symbol MIST. Founded in 2005, Milestone is the developer of etripamil, a nasal spray formulation of calcium channel blockers used to terminate episodes of transient cardiovascular conditions. Milestone has raised roughly $220 million in venture capital financing. This includes $105 million raised last year /canada/2018/10/milestone-pharmaceuticals-secures-80-mln-in-rtw-led-round/ led by RTW Investments.
- Biotech firm Dyne Therapeutics nabs $50 mln Series A
Cambridge, Massachusetts-based Dyne Therapeutics, a new biotechnology company, has secured $50 million in Series A funding. The investors were Atlas Venture, Forbion and MPM Capital.
- Canadian VC climbs to 18-year high in 2018 as top deals raise $1.4 bln
Canada’s venture capital market broke records in 2018, its ninth straight year of growth. The milestones included the most financings sized $100 million or more – ever. That made the market’s top 10 VC financings especially cash-intensive. In all, they drew $1.4 billion from investors, up 17 percent from the $1.2 billion raised by the top 10 deals in 2017. The number is based on PE Hub Canada’s list of the largest financings announced in 2018, supplemented by preliminary data from Refinitiv. It points to the considerable influence of late-stage rounds in technology investment activity, which reached a total of $4.3 billion last year, a nearly two-decade high.